Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis
- 16 June 2020
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (1) , 133-142
Abstract
Objectives To analyze the effect of disease-modifying antirheumatic drugs (DMARDs) on the outcome of interstitial lung disease secondary to rheumatoid arthritis (RA-ILD). Patients and methods We performed a multicenter, prospective, observational study of patients with RA-ILD receiving DMARDs between 2015 and 2017. The patients were assessed using high-resolution computed tomography and pulmonary function tests at baseline and at 24 months. The radiological assessment was centralized. The main outcome measure at 24 months was changed in lung function (improvement, stabilization, worsening, or death). We recorded the 28-joint Disease Activity Score 28 (DAS28) and adverse events. A logistic regression analysis was performed to identify factors associated with worsening of ILD. Results After 24 months, lung disease was stabilized in 40 patients (57.1%), improved in 8 (11.4%), and worse in 21 (30.0%). One patient (1.4%) died. The factors associated with worsening of ILD in the multivariate analysis were treatment with abatacept, tocilizumab, or rituximab (OR, 0.102 [95%CI, 0.015–0.686]), DAS28 (OR, 1.969 [95%CI, 1.005–3.857]), and smoking (OR, 6.937 [95%CI, 1.378–4.900]). During follow-up, 30 patients (42.9%) experienced an adverse event, which was severe in 12 cases (17.1%). Conclusions Lung function is stable and inflammatory activity well controlled in most patients with RA-ILD receiving treatment with DMARDs. Non-anti-TNF DMARDs reduce the risk of worsening of lung disease in 90% of patients. The inflammatory activity of RA and smoking, on the other hand, are associated with worsening. Key Points • We have performed prospectively evaluated lung and joint function in patients with RA-ILD receiving treatment with various DMARDs. • In our study, the lung function is stable and inflammatory activity well controlled in most patients with RA-ILD receiving treatment with DMARDs. • Neither csDMARDs nor anti-TNF agents were associated with a significant risk of worsening of lung disease, whereas non-anti-TNF bDMARDs could reduce the risk of worsening of lung disease. • Smoking and poor control of joint involvement were the main factors associated with worsening of lung disease.Keywords
All Related Versions
Funding Information
- Sociedad Española de Reumatología (Grant for Medical Researchers of the “Fundación Española de Reumatología” 2019.)
This publication has 32 references indexed in Scilit:
- Analysis of clinical–analytical characteristics in patients with rheumatoid arthritis and interstitial lung disease: Case–control studyReumatología Clínica (English Edition), 2021
- Rheumatoid arthritisThe Lancet, 2016
- Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature reviewSeminars in Arthritis and Rheumatism, 2014
- Methotrexate and Lung Disease in Rheumatoid Arthritis: A Meta‐Analysis of Randomized Controlled TrialsArthritis & Rheumatology, 2014
- Interstitial Lung Disease in Patients with Rheumatoid Arthritis: Spontaneous and Drug InducedDrugs, 2014
- Rheumatoid Arthritis–Interstitial Lung Disease–associated MortalityAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Rheumatoid Arthritis Interstitial Lung Disease: Mycophenolate Mofetil as an Antifibrotic and Disease-Modifying Antirheumatic DrugArchives of internal medicine (1960), 2008
- Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritisClinical Rheumatology, 2008
- Autoimmune Diseases Induced by TNF-Targeted TherapiesMedicine, 2007
- Death rates and causes of death in patients with rheumatoid arthritis: a population‐based studyScandinavian Journal of Rheumatology, 2004